Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rocket Pharmaceuticals Inc RCKT

Healthcare Biotechnology
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic... see more

Recent & Breaking News (NDAQ:RCKT)

Rocket Pharmaceuticals Announces Participation at the SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference

Business Wire July 31, 2019

Rocket Pharmaceuticals Announces Patient Dosing Has Commenced in Phase 1 Clinical Trial of RP-A501, the First Gene Therapy to Treat a Monogenic Heart Failure Syndrome

Business Wire June 18, 2019

Rocket Pharmaceuticals Sponsors 3rd Annual PKD Patients' Forum

Business Wire May 29, 2019

Rocket Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

Business Wire May 8, 2019

Rocket Pharmaceuticals Announces Participation at the Bank of America Merrill Lynch 2019 Healthcare Conference

Business Wire May 7, 2019

Rocket Pharmaceuticals Presents Preclinical Data of RP-A501 for Danon Disease at the American Society of Gene and Cell Therapy 2019 Annual Meeting

Business Wire May 2, 2019

Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine (CIRM)

Business Wire April 30, 2019

Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Business Wire April 18, 2019

Rocket Pharmaceuticals Prices Public Offering of Common Stock

Business Wire April 15, 2019

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Business Wire April 15, 2019

Rocket Pharmaceuticals Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting

Business Wire April 15, 2019

Rocket Pharmaceuticals Announces Presentations at the American College of Cardiology 2019 Annual Meeting

Business Wire March 15, 2019

Rocket Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of RP-L102 in the U.S.

Business Wire March 12, 2019

Rocket Pharmaceuticals Sponsors Clinical Trial at University of California, Los Angeles (UCLA)

Business Wire March 11, 2019

Rocket Pharmaceuticals Reports Full Year 2018 Financial Results and Operational Highlights

Business Wire March 7, 2019

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

Business Wire March 5, 2019

Rocket Pharmaceuticals Recognizes Rare Disease Day® 2019

Business Wire February 28, 2019

Rocket Pharmaceuticals Announces Publication of Comprehensive Review of Danon Disease Cases in the International Journal of Cardiology

Business Wire February 26, 2019

Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference

Business Wire February 20, 2019

Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy for Danon Disease

Business Wire January 22, 2019